Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer

Combination therapy represents an effective therapeutic approach to overcome hepatocellular cancer (HCC) resistance to immune checkpoint blockade (ICB). Based upon previous work demonstrating that nanoliposome C6‐ceramide (LipC6) not only induces HCC apoptosis but also prevents HCC‐induced immune to...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xiaoqiang, Wu, Feng, Kim, Sung Hoon, Kaifi, Jussuf T., Kimchi, Eric T., Snyder, Helena, Illendula, Anuradha, Fox, Todd, Kester, Mark, Staveley‐O'Carroll, Kevin F., Li, Guangfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297193/
https://www.ncbi.nlm.nih.gov/pubmed/35294071
http://dx.doi.org/10.1096/fj.202101707R

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297193/
https://www.ncbi.nlm.nih.gov/pubmed/35294071
http://dx.doi.org/10.1096/fj.202101707R

Ejemplares similares